MARKET VECTORS® ETFs
by Van Eck® Global

Pharmaceutical ETF (PPH)

JUNE 30, 2014

Fund Description

The Market Vectors Pharmaceutical ETF seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors US Listed Pharmaceutical 25 Index. The Index is a rules based index intended to track the overall performance of 25 of the largest U.S. listed, publicly traded pharmaceutical companies.

Performance History (%)

AS OF JUNE 30, 2014		LIFE	1M	3M	YTD	1YR	3YR	5YR
INDEX (MVPPHTR)		27.00%	3.13%	6.92%	17.38%	39.03%	–	–
FUND	NAV	27.15%	3.09%	6.93%	17.86%	39.16%	–	–
	SHARE PRICE	27.66%	3.07%	7.04%	18.03%	39.25%	–	–
AS OF MARCH 31, 2014								
INDEX (MVPPHTR)		26.59%	-1.91%	9.78%	9.78%	32.46%	–	–
FUND	NAV	26.75%	-1.91%	10.22%	10.22%	32.58%	–	–
	SHARE PRICE	27.26%	-1.93%	10.27%	10.27%	32.43%	–	–

Periods greater than one year are annualized.

The performance data quoted represents past performance. Past performance is not a guarantee of future results. Performance information for the Fund reflects temporary waivers of expenses and/or fees. Had the Fund incurred all expenses, investment returns would have been reduced. Investment return and value of the shares of the Fund will fluctuate so that an investor's shares, when sold, may be worth more or less than their original cost. Performance may be lower or higher than performance data quoted. Fund returns reflect dividends and capital gains distributions. Net asset value (NAV) per share is calculated by subtracting total liabilities from the total assets, then dividing by the number of shares outstanding. Share price is the last price at which shares were traded on the Fund's primary listing exchange. Fund shares may trade at, above or below NAV. Performance current to the most recent month end available by calling 888.MKT.VCTR or by visiting marketvectorsetfs.com.

Fund Details

FUND TICKER	PPH
INTRADAY NAV (IIV)	PPH.IV
INDEX TICKER	MVPPHTR
NET ASSETS ($M)	346.55
OPTIONS	Available
EXCHANGE	NYSE Arca
COMMENCEMENT DATE	12/20/11

Fund Expenses[1]

MANAGEMENT FEE	0.35%
OTHER EXPENSES	0.08%
GROSS EXPENSE RATIO	0.43%
WAIVERS AND REIMBURSEMENTS	-0.08%
NET EXPENSE RATIO	0.35%

[1]Expenses are capped contractually until 2/1/2015. Cap excludes certain expenses, such as interest.

Index returns assume the reinvestment of all income and do not reflect any management fees or brokerage expenses associated with Fund returns. Returns for actual Fund investors may differ from what is shown because of differences in timing, the amount invested and fees and expenses. You cannot invest directly in an Index.

Fund Data

No. of Securities	25
Currency	USD
Price/Earnings Ratio	25.46
Price/Book Ratio	3.86
Avg. Weighted Market Cap ($M)	124,751.8
30-Day SEC Yield*	1.79%
52 Week High/Low	62.30/45.00

*In the absence of temporary waivers or reimbursements, the 30-Day SEC Yield would have been 1.61%.

Fund Domicile Breakdown

United States	58.7%
Switzerland	10.1%
United Kingdom	9.2%
France	5.2%
Denmark	5.1%
Israel	4.4%
Ireland	4.1%
Canada	3.2%

Fund Holdings (weight in %)

Johnson & Johnson	JNJ US	10.83%
Novartis AG Sponsored ADR	NVS US	10.08%
Pfizer Inc.	PFE US	7.31%
Merck & Co., Inc.	MRK US	5.70%
Sanofi Sponsored ADR	SNY US	5.25%
Novo Nordisk A/S Sponsored ADR Class B	NVO US	5.07%
GlaxoSmithKline plc Sponsored ADR	GSK US	4.80%
Eli Lilly and Company	LLY US	4.59%
AbbVie, Inc.	ABBV US	4.57%
Allergan, Inc.	AGN US	4.55%
Bristol-Myers Squibb Company	BMY US	4.53%
Abbott Laboratories	ABT US	4.49%
Teva Pharmaceutical Industries Limited Sponsored ADR	TEVA US	4.42%
AstraZeneca PLC Sponsored ADR	AZN US	4.39%
Shire PLC Sponsored ADR	SHPG US	4.10%
Subtotal – Top 15		84.66%
Remaining Constituents		15.34%
Total		100.00%

For a complete listing of Constituents, please visit vaneck.com/PPH

These are not recommendations to buy or sell any security.

Averages are market weighted. Price/Book Ratio is the price of a security divided by the book value per share of the security. Price/Earnings Ratio is the price of a security divided by the last twelve months earnings per share of the security. Market Capitalization of an individual, publicly traded company is calculated by multiplying the company's stock price by the total number of its shares outstanding.

Investments concentrated in the pharmaceutical sector may be subject to more volatility than investments in a diverse group of sectors. They are subject to the risks associated with the sector including, among others, costs associated with research and development, intellectual property rights and regulatory approval by the U.S. Food and Drug Administration. Additionally, the Fund is subject to changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks inherent to international investing. Investing in securities of medium-sized companies may involve greater risk than is customarily associated with investing in large companies. The Fund is considered non-diversified and may be subject to greater risks than a diversified fund. Investors should be willing to accept a high degree of volatility and the potential of significant loss. See the Fund's prospectus for more complete information regarding investment risks.

Market Vectors US Listed Pharmaceutical 25 Index (the "Index") is the exclusive property of Market Vectors Index Solutions GmbH (a wholly owned subsidiary of the Adviser), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards Market Vectors Index Solutions GmbH, Solactive AG has no obligation to point out errors in the Index to third parties. Market Vectors Pharmaceutical ETF (the "Fund") is not sponsored, endorsed, sold or promoted by Market Vectors Index Solutions GmbH and Market Vectors Index Solutions GmbH makes no representation regarding the advisability of investing in the Fund.

Van Eck Securities Corporation, Distributor

NOT FDIC INSURED - NO BANK GUARANTEE - MAY LOSE VALUE

Investing involves substantial risk and high volatility, including possible loss of principal. An investor should consider the investment objective, risks, charges and expenses of the Fund carefully before investing. To obtain a prospectus and summary prospectus, which contain this and other information, call 888.MKT.VCTR or visit marketvectorsetfs.com. Please read the prospectus and summary prospectus carefully before investing.

Fund shares are not individually redeemable and will be issued and redeemed at their NAV only through certain authorized broker-dealers in large, specified blocks of shares called creation units and otherwise can be bought and sold only through exchange trading. Creation units are issued and redeemed principally in kind. Shares may trade at a premium or discount to their NAV in the secondary market.

Van Eck Global SINCE 1955